Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease

• Status: Completed
• Trial end date: 2010-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Impaired renal function is associated with reduced responsiveness to clopidogrel. There are no studies which have shown a means by which to overcome platelet hyporesponsiveness in patients with chronic kidney disease (CKD). The purpose of this study was to determine the functional impact of cilostazol in patients with CKD undergoing hemodialysis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kyunghee University Medical Center
• Treatments: Cilostazol; Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• CKD patients undergoing chronic hemodialysis and PCI for stable coronary artery disease

Exclusion Criteria:

• known allergies to aspirin, clopidogrel, or cilostazol thienopyridine use before enrollment

• concomitant use of other anti-thrombotic drugs (oral anticoagulants and dipyridamole)

• platelet count <100 x 106/μL

• hematocrit < 25%

• liver disease (bilirubin > 2 mg/dl)

• active bleeding or bleeding diathesis

• gastrointestinal bleeding within the last 6 months

• hemodynamic instability

• acute coronary or cerebrovascular event within 3 months

• malignancy

• concomitant use of a cytochrome P450 inhibitor or a non-steroidal anti-inflammatory drug

• recent treatment (<30 days) with a glycoprotein IIb/IIIa antagonist.